Rockefeller Capital Management
ZYNE

Rockefeller Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Rockefeller Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,000
Closed -$1K – 4123
2022
Q4 		$1K Hold
2,000
– – ﹤0.01% 3796
2022
Q3 		$1K Hold
2,000
– – ﹤0.01% 3816
2022
Q2 		$2K Hold
2,000
– – ﹤0.01% 3872
2022
Q1 		$4K Hold
2,000
– – ﹤0.01% 3462
2021
Q4 		$5K Buy
+2,000
New +$7.4K ﹤0.01% 3309

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's ZYNE Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 2,000 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in ZYNE in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 2,000 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and held it in 5 quarters.
  • Rockefeller Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $5K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.